AtaiBeckley看到迷幻抗抑郁药的中期结果有希望

2026-03-17 22:24

AtaiBeckley (ATAI) said that phase 2a results indicated that BPL-003 (mebufotenin benzoate nasal spray), which has psychedelic effects, led to long-term antidepressant effects in individuals with treatment-resistant depression.
Data came from a cohort of 12 patients in a 12-week, open-label trial of a single 10 mg dose who were not also on any antidepressants. Results showed that BPL-003 contributed to a mean Montgomery–Åsberg Depression Rating Scale (MADRS) total score reduction of 12.6 points by day 2, which was maintained over 12 weeks to a mean MADRS score of 14.5 at day 85.
Also, mean Snaith-Hamilton Pleasure Scale (SHAPS) scores improved from 8.4 at baseline to 1.5 at Day 85, indicating an absence of anhedonia, the inability the experience joy or pleasure. The drug was also well tolerated with no serious adverse events.
AtaiBeckley noted that a phase 3 program for BPL-003 is on schedule to begin in Q2.

More on AtaiBeckley